Craddock Charles, Earwaker Philip, Fittall Matthew, Fontana Elisa, Ganesh Divya, Gerlinger Marco, Ghafoor Qamar, Jones Robert P, Kunene Victoria, Lee Lennard, Lee Rebecca, Lee Siow-Ming, Linch Mark, Little Martin, Liu Justin, McKenzie Hayley, Petty Russell, Pinato David J, Powles Thomas, Protheroe Andrew, Robinson Tim, Ross Paul J, Shiu Kai Keen, Spicer James, Symeonides Stefan, Tilby Michael, Vimalachandran Dale, Wang Jenny Y, Wardley Andrew, Winter Helen
University of Warwick Warwick Clinical Trials Unit, Coventry, United Kingdom of Great Britain and Northern Ireland.
Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom of Great Britain and Northern Ireland.
Camb Prism Precis Med. 2025 Jan 20;3:e1. doi: 10.1017/pcm.2024.5. eCollection 2025.
Vaccines have revolutionised the field of medicine, eradicating and controlling many diseases. Recent pandemic vaccine successes have highlighted the accelerated pace of vaccine development and deployment. Leveraging this momentum, attention has shifted to cancer vaccines and personalised cancer vaccines, aimed at targeting individual tumour-specific abnormalities. The UK, now regarded for its vaccine capabilities, is an ideal nation for pioneering cancer vaccine trials. This article convened experts to share insights and approaches to navigate the challenges of cancer vaccine development with personalised or precision cancer vaccines, as well as fixed vaccines. Emphasising partnership and proactive strategies, this article outlines the ambition to harness national and local system capabilities in the UK; to work in collaboration with potential pharmaceutic partners; and to seize the opportunity to deliver the pace for rapid advances in cancer vaccine technology.
疫苗彻底改变了医学领域，根除并控制了许多疾病。近期大流行疫苗的成功凸显了疫苗研发和部署的加速步伐。借助这一势头，关注点已转向癌症疫苗和个性化癌症疫苗，旨在针对个体肿瘤特异性异常。英国如今因其疫苗能力而受到关注，是开展癌症疫苗试验的理想国家。本文召集专家分享见解和方法，以应对个性化或精准癌症疫苗以及常规疫苗在癌症疫苗研发方面的挑战。本文强调合作和积极策略，概述了利用英国国家和地方系统能力的抱负；与潜在制药合作伙伴合作；并抓住机会推动癌症疫苗技术快速进步。
